Prostate-specific antigen screening, a procedure designed to detect prostate cancer, recently received a failing grade from the U.S. Preventive Services Task Force. That report has weighed on Intuitive Surgical's (NASDAQ:ISRG) growth, because PSA screenings have been a large driver of prostatectomies, one of the company's flagship procedures. In this video, Motley Fool health care analyst Brenton Flynn dives into the impact this trend is having on the company and where it might find growth in other areas.
1 Trend Cutting Into Intuitive Surgical's Growth
You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
NASDAQ: ISRG
Intuitive Surgical

Screening changes weigh on Intuitive's growth
Brenton Flynn has no positions in the stocks mentioned above. The Motley Fool owns shares of Intuitive Surgical and MAKO Surgical. Motley Fool newsletter services recommend Intuitive Surgical and MAKO Surgical. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Invest Smarter with The Motley Fool
Join Over Half a Million Premium Members Receiving…
- New Stock Picks Each Month
- Detailed Analysis of Companies
- Model Portfolios
- Live Streaming During Market Hours
- And Much More
Motley Fool Investing Philosophy
- #1 Buy 25+ Companies
- #2 Hold Stocks for 5+ Years
- #3 Add New Savings Regularly
- #4 Hold Through Market Volatility
- #5 Let Winners Run
- #6 Target Long-Term Returns
Why do we invest this way? Learn More
Stocks Mentioned

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles





Motley Fool Returns

Market-beating stocks from our award-winning analyst team.
Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/07/2023.
Discounted offers are only available to new members. Stock Advisor list price is $199 per year.
Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.

Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.